Preclinical studies on the use of a P-selectin-blocking monoclonal antibody to halt progression of myelofibrosis in the Gata1low mouse model

•Treatment with RB40.34 targeting murine P-selectin and ruxolitinib, in combination, is more effective than either drug alone in rescuing myelofibrosis in Gata1low mice.•This drug combination reduced fibrosis, bone deposition and neoangiogenesis while restoring hematopoiesis in bone marrow and reducing hematopoiesis in spleen.•Mechanistically, the drug combination may have exerted their effects by reducing the TGF-β and CXCL1 content of the bone marrow.•These data provide pre-clinical evidence that P-selectin antibodies and Ruxolitinib in combination may be more effective than Ruxulotinib alone to treat myelofibrosis.